A Phase 2 Study With Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Patients With Microsatellite Stable Refractory Metastatic Colorectal Cancer

Trial Profile

A Phase 2 Study With Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Patients With Microsatellite Stable Refractory Metastatic Colorectal Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Nivolumab (Primary) ; Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 20 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 11 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top